Insulet Corporation $PODD Shares Acquired by Kayne Anderson Rudnick Investment Management LLC

Key Points

• Kayne Anderson Rudnick Investment Management LLC increased its stake in Insulet Corporation by 1,316.5%, acquiring 179,850 additional shares to own approximately 193,511 shares valued at $50.8 million.
• Insulet reported a significant earnings beat with $1.17 EPS, surpassing estimates of $0.92, and a revenue increase of 32.9% year-over-year to $649.1 million.
• Research analysts are optimistic about Insulet's future, with the majority issuing a Buy rating, leading to an average target price of $332.71 for the stock.

Kayne Anderson Rudnick Investment Management LLC raised its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 1,316.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 193,511 shares of the medical instruments supplier's stock after purchasing an additional 179,850 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC owned about 0.28% of Insulet worth $50,818,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its position in Insulet by 55.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock valued at $1,376,000 after acquiring an additional 1,867 shares during the period. Farther Finance Advisors LLC grew its holdings in shares of Insulet by 85.1% during the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after purchasing an additional 412 shares during the period. QRG Capital Management Inc. increased its position in Insulet by 75.6% during the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock worth $533,000 after purchasing an additional 874 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Insulet by 225.4% in the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock valued at $408,000 after buying an additional 1,075 shares during the period. Finally, State of Alaska Department of Revenue raised its holdings in Insulet by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier's stock valued at $2,156,000 after buying an additional 210 shares during the period.

Insulet Stock Up 1.0%

PODD traded up $3.25 during trading on Thursday, hitting $337.60. The company had a trading volume of 457,992 shares, compared to its average volume of 758,884. Insulet Corporation has a 1-year low of $199.68 and a 1-year high of $337.84. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company has a market cap of $23.76 billion, a PE ratio of 102.61, a P/E/G ratio of 2.78 and a beta of 1.35. The business has a 50-day moving average of $302.59 and a 200-day moving average of $286.87.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the previous year, the firm earned $0.55 EPS. The company's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

PODD has been the subject of several research reports. Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Raymond James Financial reaffirmed an "outperform" rating and set a $360.00 price target (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a report on Tuesday, May 13th. The Goldman Sachs Group began coverage on Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective on the stock. Finally, Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.